NCT05695976View on ClinicalTrials.gov

GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

SuspendedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
GlioblastomaGlioma, Malignant
Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke University, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Personalis Inc.
All Listed Sponsors
collaborator

Personalis Inc.

INDUSTRY

lead

Duke University

OTHER

NCT05695976 - GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | Biotech Hunter | Biotech Hunter